Parsatuzumab

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Parsatuzumab (Anti-EGFL7; RG 7414) 是一种人源化单克隆抗体，作为免疫调节剂与 EGFL7 结合。Parsatuzumab 选择性阻断 EGFL7 与内皮细胞之间的相互作用，可能抑制血管再生，降低血管内皮生长因子 (VEGF) 抑制。

Parsatuzumab (Anti-EGFL7; RG 7414) is a humanized monoclonal antibody, acts as an immunomodulator and binds to EGFL7. Parsatuzumab selectively blocks the interaction between EGFL7 and endothelial cells, potentially inhibiting vascular regrowth and reducing vascular endothelial growth factor (VEGF) inhibition.

EGFL7 is a vascular-restricted extracellular matrix protein that promotes endothelial cell adhesion and survival.Parsatuzumab (48 h) inhibits cell proliferation and increases apoptosis against patient-derived xenograft (PDX) cells.Cell Viability Assay Cell Line:Patient-derived xenograft (PDX) cells Concentration:/Incubation Time:48 hours Result:Inhibited cell proliferation by 70% from 20%, and resulted in apoptosis increases by 67-87% from 8-17%.

Parsatuzumab (anti-EGFL7) enhances the antiangiogenesis, tumor growth control, and survival associated with antiVEGF monotherapy in several xenograft and genetically engineered murine tumor models. Parsatuzumab (50 mg/kg; i.v.; 3 times per week) targets EGFL7 and inhibits mantle cell lymphoma (MCL) cell growth and prolongs survival in mouse models of MCL.Animal Model:NSG mice injected with Rec1 cells (s.c.)Dosage:50 mg/kg Administration:Intravenous injection; 3 times per week; sacrificed mice when tumor reached end point criteriaResult:Significantly decreased tumor volume than IgG and increased survival of mice.

——

Angiogenesis

VEGFR

VEGFR

——

——

1312797-14-0

——

>98% (HPLC)

——

——

——

(-20℃)

With Ice Pack

≥ 2 years